Krystal Biotech, Inc. Common Stock (KRYS) Financials
Key financial figures for Krystal Biotech, Inc. Common Stock (Q3 2026).
Krystal Biotech reported Q3 2026 VYJUVEK net product revenue of $127.3 million, up 30% from $97.8 million a year ago, alongside a $400 million buyback authorization and lower FY 2026 operating expense guidance. Net product revenue was $127.3 million versus $97.8 million in Q3 2025 (+30%), with a 94% gross margin; the 10-Q splits it into United States $95.3 million (vs $92.9 million), Europe $23.3 million (vs $4.9 million) and Japan $8.8 million (vs none). Income from operations rose to $71.1 million from $41.4 million (+72%, calculated) as total operating expenses were flat at $56.2 million versus $56.4 million; SG&A fell to $33.7 million from $37.6 million while R&D was $14.9 million versus $14.6 million. On the outlook: FY 2026 non-GAAP combined R&D and SG&A expense (excluding stock-based compensation) guidance lowered to $155.0 million - $165.0 million from $175.0 million - $195.0 million in the Q2 2026 release. The release gives no revenue guidance. Figures are for Q3 2026, as Krystal Biotech, Inc. reported them.
- Revenue
- $127M
- Net Income
- $63M
- EPS
- $2.13
- Total Assets
- $1.6B
- Operating Cash Flow
- $91M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $127M | $63M | $2.05 | 55.87% | $90M |
| Q2 FY2026 | $119M | $55M | $1.79 | 49% | $71M |
| Q1 FY2026 | $116M | $56M | $1.83 | 46.14% | $73M |
| Q4 FY2025 | $107M | $51M | $1.70 | 41.49% | $75M |
| Q3 FY2025 | $98M | $79M | $2.66 | 42.3% | $38M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $389M | $205M | $6.84 | 41.45% | $189M |
| FY2024 | $291M | $89M | $3.00 | 22.61% | $119M |
| FY2023 | $51M | $11M | $0.39 | -216.43% | -$101M |
Frequently asked questions
What was Krystal Biotech, Inc.'s revenue last quarter?
Krystal Biotech, Inc. reported revenue of $127.3 million for Q3 FY2026, up 30.2% from the same period a year earlier.
Is Krystal Biotech, Inc. profitable?
Yes. Krystal Biotech, Inc. reported net income of $63.1 million for Q3 FY2026, a net margin of 49.53% on revenue.
How has Krystal Biotech, Inc.'s margin trended?
Operating margin was 55.87% in Q3 FY2026, compared with 42.3% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Krystal Biotech, Inc. generate?
Krystal Biotech, Inc. generated free cash flow of $90.3 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Krystal Biotech, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.